Keyword Analysis & Research: biontech
Keyword Research: People who searched biontech also searched
Search Results related to biontech on Search Engine
-
BioNTech
https://www.biontech.com/int/en/home.html
WEBBioNTech. We are a global immunotherapy powerhouse aspiring to translate science into survival. Read more. Interest Selector. Our mission. We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. We believe in scientific rigor, innovation and passion as driving force.
DA: 35 PA: 42 MOZ Rank: 94
-
BioNTech US
https://www.biontech.com/int/en/home/about/biontech-us-website.html
WEBA transatlantic leader in individualized neoantigen-targeted T cell therapies. Based in Cambridge, MA, BioNTech US serves as BioNTech’s North American headquarters and is an important part of our global effort to pioneer the development of next-generation immuno-oncology therapies.
DA: 57 PA: 98 MOZ Rank: 90
-
BioNTech - Wikipedia
https://en.wikipedia.org/wiki/BioNTech
WEBBioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
DA: 25 PA: 67 MOZ Rank: 20
-
Inside the hunt for a Covid-19 vaccine: how BioNTech made the …
https://www.ft.com/content/c4ca8496-a215-44b1-a7eb-f88568fc9de9
WEBNov 13, 2020 · A vaccine candidate developed by the company they co-founded 12 years ago, BioNTech, was more than 90 per cent effective in preventing the disease — a far higher level than the widely-used jabs...
DA: 57 PA: 66 MOZ Rank: 12
-
Pfizer–BioNTech COVID-19 vaccine - Wikipedia
https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine
WEBThe Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
DA: 40 PA: 88 MOZ Rank: 60
-
BioNTech’s Founders on A.I. and the Future of Cancer Treatment
https://www.nytimes.com/2023/12/05/special-series/artificial-intelligence-cancer-vaccine-biontech.html
WEBDec 5, 2023 · Dr. Ugur Sahin and Dr. Özlem Türeci are pioneers in the field of mRNA vaccines and personalized cancer immunotherapies, and are the scientific founders of BioNTech.
DA: 46 PA: 5 MOZ Rank: 36
-
The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you …
https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know
WEBUpdated 18 August 2022, to reflect the latest SAGE recommendations. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance ...
DA: 58 PA: 44 MOZ Rank: 94
-
FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 …
https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations
WEBSep 22, 2021 · Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered...
DA: 51 PA: 88 MOZ Rank: 74
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full
WEBDec 11, 2020 · 2024. Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older. Monday, August 23, 2021 - 11:57am. View pdf copy Copy to clipboard Open in tab. COMIRNATY is the first COVID-19 vaccine to be granted FDA approval.
DA: 6 PA: 67 MOZ Rank: 42
-
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
WEBNov 18, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints.
DA: 14 PA: 13 MOZ Rank: 15